Human genetic variants causing loss-of-function (LoF) of protein-coding genes provide natural in vivo models of gene inactivation, which are powerful indicators of gene function and the potential toxicity of therapeutic inhibitors targeting these genes 1,2 . Gain-of-kinase-function variants in LRRK2 are known to significantly increase the risk of Parkinson's disease 3,4 , suggesting that inhibition of LRRK2 kinase activity is a promising therapeutic strategy. Whilst preclinical studies in model organisms have raised some on-target toxicity concerns 5-8 , the biological consequences of LRRK2 inhibition have not been well characterized in humans. Here we systematically analyse LoF variants in LRRK2 observed across 141,456 individuals sequenced in the Genome Aggregation Database (gnomAD) 9 and over 4 million participants in the 23andMe genotyped dataset, to assess their impact at a molecular and phenotypic level. After thorough variant curation, we identify 1,358 individuals with high-confidence predicted LoF variants in LRRK2, several with experimental validation. We show that heterozygous LoF of LRRK2 reduces LRRK2 protein level by ~50% but is not associated with reduced life expectancy, or with any specific phenotype or disease state. These data suggest that therapeutics that downregulate LRRK2 levels or kinase activity by up to 50% are unlikely to have major on-target safety liabilities. Our results demonstrate the value of large scale genomic databases and phenotyping of human LoF carriers for target validation in drug discovery.
Despite these promising indications, concerns remain about the potential toxicity of LRRK2 inhibitors. These mainly arise from preclinical studies, where homozygous knockouts of LRRK2 in mice, and high dose toxicology studies of LRRK2 kinase inhibitors in rats and primates, have shown abnormal phenotypes in lung, kidney and liver [5] [6] [7] [8] . While model organisms have been invaluable in understanding the function of LRRK2, they also have important limitations as exemplified by the inconsistencies in the phenotypic consequences of reduced LRRK2 activity seen among yeast, fruit flies, worm, mice, rats and non-human primates 23 . Complementary data from natural human knockouts are critical for understanding both gene function and the potential consequences of a long-term reduction in LRRK2 kinase activity in humans.
Large-scale human genetics is an increasingly powerful source of data for the discovery and validation of therapeutic targets in humans 1 . pLoF variants, predicted to largely or entirely abolish the function of affected alleles, are a particularly informative class of genetic variation. Such variants are natural models for life-long organism-wide inhibition of the target gene, and can provide information about both the efficacy and safety of a candidate target 2, [24] [25] [26] [27] . However, pLoF variants tend to be rare in human populations 28 , and are also enriched for both sequencing and annotation artefacts 29 . As such, leveraging pLoF variation in drug target assessment typically requires very large collections of genetically and phenotypically characterized individuals, combined with deep curation of the target gene and candidate variants 30 .
We identified LRRK2 pLoF variants, and characterized the associated phenotypic changes, in two large cohorts of genetically characterized individuals. Firstly, we annotated LRRK2 pLoF variants in the gnomAD 2.1 data set, which contains 125,748 exomes and 15,708 genomes from unrelated individuals sequenced as part of various disease-specific and population genetic studies, and is described in detail in an accompanying publication 9 . We identified 633 individuals in gnomAD with 123 unique candidate LRRK2 LoF variants, a combined carrier frequency of 0.45%. All variants were observed only in the heterozygous state. Compared to the spectrum observed across all genes, LRRK2 is not significantly depleted for LoF variants (loss-of-function observed/expected upper bound fraction (LOEUF) 9 =0.64).
To ensure that the 123 identified variants are indeed expected to cause LoF, we manually curated them to remove those of low-quality or with annotation errors (Figure 1a ; Supplementary Table 1 ). We removed twelve variants identified either as low-confidence by the Loss-of-function Transcript Effect Estimator (LOFTEE; 6 variants in 285 individuals) 9 , or manually curated as low-quality or unlikely to cause true LoF (6 variants in 93 individuals; see methods). This included one variant -T-C), found in 77 gnomAD carriers, that was identified in an individual with RNA-seq data in the Genotype-Tissue Expression (GTEx) project 31 . Assessing the read distribution of a linked heterozygous variant in this individual showed convincingly that the variant has no discernible effect on transcript splicing (Supplementary Figure 1 ). This analysis reaffirms the importance of thorough curation of candidate LoF variants 30 , and results in a final gnomAD dataset of 255 individuals with 111 unique high-quality pLoF variants ( Figure 1a ), with an overall carrier frequency of 0.19%. A subset of 25 samples with 19 unique LRRK2 LoF variants with DNA available were all successfully validated by Sanger sequencing (Supplementary  Table 2 ).
Secondly, we examined LRRK2 pLoF variants in over four million consented research participants from the personal genetics company 23andMe, Inc. Participants have been genotyped on a variety of platforms, and imputed against a reference panel comprising 56.5 million variants from 1000 Genomes phase 3 32 , and UK10K 33 . Eight putative LRRK2 LoF variants were identified in the 23andMe cohort (LOFTEE high-confidence). One variant was the same splice variant that was excluded from gnomAD after inspection of GTEx data (Supplementary Figure 1) and was similarly excluded here. Carrier status of the remaining seven variants was confirmed using Sanger sequencing. The resulting cohort consisted of 749 individuals, each of whom is a Sanger-confirmed carrier for one of three LoF variants ( Supplementary Table 3 ). Subsequent expansion of the 23andMe dataset identified 354 additional putative carriers of rs183902574. Across the two most frequent pLoF alleles we observed an extremely small number (<5) of sequence-confirmed homozygotes; however, given the very small number of observations, we can make no robust inference except that homozygous inactivation of LRRK2 appears to be compatible with life. For the remainder of this manuscript we focus on heterozygous pLoF carriers.
The combined datasets from gnomAD and 23andMe describe a total of 1,358 carrier individuals with 111 unique LRRK2 pLoF variants. These variants are found across all major continental populations (Figure 1b; Supplementary Figure 2 ) and show neither any obvious clustering along the length of the LRRK2 protein, nor specific enrichment or depletion in any of the known annotated protein domains (Chi-square P=0.23; Figure 1c ), consistent with signatures of true LoF 30 . . pLoF variants seen more than 10 times appear in colour with remaining variants in grey. LRRK2 pLoF variants are mostly individually extremely rare (less than 1/10,000 carrier frequency), with the exception of two nonsense variants almost exclusively restricted to the admixed American/Latino population (Cys1313Ter and Arg1725Ter), and two largely Non-Finnish European-specific variants (Leu2063Ter and Arg772Ter). All variant protein descriptions are with respect to ENSP00000298910. c) Schematic of the LRRK2 gene with pLoF variants marked by position, with the height of the marker corresponding to allele count in gnomAD. The 51 exons are shown as rectangles coloured by protein domain, with the remaining exons in grey. The three variants genotyped in the 23andMe cohort are annotated with their sample count in black text.
To confirm that LRRK2 pLoF variants lead to a reduction in LRRK2 protein levels, we analysed total protein lysates from cell lines with three unique pLoF variants by immunoblotting. We obtained lymphoblastoid cell lines (LCLs) from two families with naturally occuring heterozygous LoF variants, and a third variant was CRISPR/Cas9 engineered into embryonic stem cells ( Supplementary  Figure 3 ), which were differentiated into cardiomyocytes. In all instances, LRRK2 protein levels were visibly reduced compared to non-carrier controls ( Figure 2 ). We next sought to determine whether lifelong lowering of LRRK2 protein levels through LoF results in an apparent reduction in life-span. We found no significant difference between the age distribution of LRRK2 pLoF variant carriers and non-carriers in either the gnomAD or 23andMe datasets (Kolmogorov-Smirnov P=0.085 and 0.46 respectively; Figure 3a ), suggesting no major impact on lifespan.
For a subset of studies within gnomAD, phenotype data is available from study or national biobank questionnaires or from linked electronic health records (for full details see online methods). We manually reviewed these records for all 60 of the 255 gnomAD LRRK2 LoF carriers for whom data were available, and recorded any phenotypes affecting the lung, liver, kidney, cardiovascular system, nervous system, immunity, and cancer (Supplementary Table 4 ). We did not find an overrepresentation of any particular phenotype or phenotype category in LRRK2 LoF carriers. In addition, for the 12 LRRK2 carriers from the Pakistan Risk of Myocardial Infarction Study (PROMIS) we observed no significant association between LRRK2 carrier status and 77 blood biomarkers, including creatinine, a widely-used marker of kidney function (Figure 3b ; Supplementary Figure 4 ; Supplementary Table 5 ).
The 23andMe dataset includes self-reported data for thousands of phenotypes across a diverse range of categories. We performed a phenome-wide association study on LRRK2 LoF carriers compared to non-carriers and found no significant association between any individual phenotype and carrier status ( Figure 3c ). In particular, we found no significant associations with any lung, liver or kidney phenotypes (Supplementary Table 6 ).
Our results indicate that approximately one in every 550 humans is heterozygous for a pLoF variant in LRRK2, resulting in a systemic lifelong decrease in LRRK2 protein levels to approximately 50% of wild-type levels, and that this partial inhibition has no discernible effect on survival or health. These results suggest that drugs that reduce LRRK2 kinase activity are unlikely to show toxicity due to ontarget effects. This observation is particularly important given that individuals at risk of PD will need to take therapeutics chronically, likely soon after clinical diagnosis and extending for decades. While initial phase I studies of the safety of LRRK2 kinase inhibitors have shown a promising safety profile 22 ,34 , these are not yet able to address the question of long-term, on-target pharmacologyrelated safety profiles. Supplementary Figure 4 . (c) Manhattan plot of phenome-wide association study results for carriers of three LRRK2 pLoF variants against non-carriers in the 23andMe cohort. Each point represents a distinct phenotype with these grouped into related categories (delineated by alternating black and grey points).
We acknowledge multiple limitations to our study. Firstly, we relied on heterogeneous phenotype data mostly derived from self-reported questionnaires. Secondly, both 23andMe and gnomAD record only age at recruitment, and participants are of a relatively young age compared to the typical age of onset for PD. Thirdly, a subset of the 23andMe individuals treated as non-carriers could be carriers of LRRK2 pLoF variants not genotyped or imputed in this dataset. Finally, the lowfrequency of naturally occuring pLoF variants in LRRK2 results in a relatively small number of carriers which could be assessed for each biomarker and phenotype. Additionally, the rarity of pLoF variants in LRRK2 prevents us from directly assessing whether LRRK2 inhibition may reduce the incidence of PD, at current sample sizes.
Despite this, our findings illustrate the value of large genetically and phenotypically characterized cohorts, combined with thorough variant curation, in exploring the safety profile of candidate drug targets. Over the coming years, the availability of complete exome or genome sequence data for hundreds of thousands of individuals who are deeply phenotyped and/or available for genotypebased recontact studies, combined with deep curation and experimental validation of candidate pLoF variants, will provide powerful resources for therapeutic target validation as well as broader studies of the biology of human genes.
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Supplementary Tables and Figures
Supplementary Table 6 : Association statistics for phenotypes specific to lung, kidney and liver (also plotted in Figure 3c ). For privacy reasons, counts of less than five are rounded. None of the phenotypes associated with carrier status, even without correction (p < 0.05). 
Supplementary Figure 4. Blood serum biomarkers in LRRK2
LoF carriers compared to the measurements in the 10,503 PROMIS parent cohort: cohort mean and standard deviations are shown in black (mean as a circle with +/-1 SD as black lines) and the LRRK2 LoF carriers as blue diamonds with the mean and standard deviations shown in grey.
Online Methods gnomAD variant annotation and curation
The gnomAD resource, including both sample and variant quality control (including sample ancestry assignment), is fully described in our companion paper 9 . gnomAD version 2.1 was used for this analysis. Putative LoF variants were defined as stop gained, frameshift or essential splice site (splice donor or splice acceptor) as annotated by the Ensembl Variant Effect Predictor 35 . Variants were included if they were annotated as LoF on any transcript expressed in the lung, liver or kidney. Variants were filtered out if they were flagged as low-confidence by the Loss-of-function Transcript Effect Estimator (LOFTEE) 9 . For the remaining variants, a manual curation was performed, including inspection of variant quality metrics, read distribution and the presence of nearby variants using the Integrative genome viewer (IGV) and splice site prediction algorithms using Alamut. For a single splice-site variant found in an individual in the GTEx project, RNA-seq reads were manually inspected to look for any effect on splicing. All available tissues were assessed with reads from lung tissue shown in Supplementary Figure 1 .
We have complied with all relevant ethical regulations. This study was overseen by the Broad Institute's Office of Research Subject Protection and the Partners Human Research Committee. Informed consent was obtained from all participants.
Sanger validation of gnomAD variant carriers
Sanger validation was performed on genomic DNA derived from peripheral blood under the following PCR conditions: 98°C 2min; 30 cycles 20sec 98°C, 20sec 54°C, 1min 72°C; 3min 72°C using the Herculase II Fusion DNA polymerase (Agilent, 600679). PCR products (5ul) were analyzed on a 2% agarose gel and the remaining product was purified with the Qiagen PCR Purification kit. Sequence analysis was performed with both PCR primers at Quintarabio. Details of variants and PCR primers used for each can be found in Supplementary Table 2 .
gnomAD phenotype curation and cohort descriptions
The below described studies with LRRK2 pLoF carriers had available phenotype data. For each study, all available records were manually reviewed to identify any reports of health problems which were categorised into the following classes: lung, liver, kidney, cardiovascular, nervous system, immune and cancer.
The Genomic Psychiatry Cohort (GPC) project
The GPC cohort is a longitudinal resource with the aim of making population-based data available through the National Institute of Mental Health (NIMH). The NIMH repository contains wholegenome sequencing data and detailed clinical and demographic data particularly focussed on schizophrenia and bipolar disorders. A large fraction of participants, 88%, have consented for recontact 36 .
The screening questionnaire consisted of 32 yes/no questions about mental health issues and 23 yes/no questions covering other medical problems including liver, digestive and cardiovascular problems. There were no specific questions relating to lung or kidney phenotypes although participants were asked to answer yes/no to having any additional health problems. If a participant answered yes to this question, we marked the existence of lung or kidney disease as 'unknown'. One sample was excluded due to conflicting questionnaire answers.
The age of the 25 LRRK2 carriers ranged from 19 to 67. Two carriers, aged 55 and 60, reported having had liver problems with 4 participants over 60 years reporting no liver problems.
The Pakistan Risk of Myocardial Infarction Study (PROMIS)
The PROMIS cohort comprises 10,503 individuals characterized using a phenotype questionnaire with >350 items covering demographic and dietary characteristics and over 80 blood biomarker measurements 37 . The predominant focus of the questionnaire was cardiac function and phenotype. Whist the participants were specifically asked to report suffering from asthma, no other lung, liver, kidney, nervous system or immune phenotypes were directly assayed so these were marked as 'unknown' for these individuals.
The 12 LRRK2 LoF carriers in PROMIS did not differ in terms of age, sex and myocardial infarction status when compared to the entire cohort. In addition, for these 12 individuals, we obtained data for up to 80 blood serum biomarkers along with summary statistics (mean, median and standard deviation) for the entire cohort. A Welch Two Sample t-test was used to test for difference between LRRK2 pLoF carriers and non-carriers for the 77 biomarkers with data for >1 carrier individual.
The Swedish Schizophrenia and Bipolar Studies
Cases with schizophrenia or bipolar disorder were identified from Swedish national hospitalization registers 38, 39 . Controls were selected at random from population registers. All individuals had whole exome sequencing data 40 . All available ICD codes from inpatient hospitalizations and outpatient specialist treatment contacts were provided for each patient.
FINRISK: the National FINRISK study
The FINRISK survey has been carried out for 40 years since 1972 every five years using independent, random and representative population samples from different parts of Finland. For this work, we used sequencing and health register data from FINRISK surveys 1992-2007 41 .
Full health records including ICD10 codes were reviewed by study coordinators who provided us with yes/no answers for each of our phenotype classes.
The BioMe biobank at The Charles Bronfman Institute for Personalized Medicine at Mount Sinai
The Mount Sinai BioMe Biobank, founded in September 2007, is an ongoing, broadly-consented electronic health record (EHR)-linked bio-and data-repository that enrolls participants nonselectively from the Mount Sinai Medical Center patient population (New York City). BioMe participants represent a broad racial, ethnic and socioeconomic diversity with a distinct and population-specific disease burden, characteristic of the communities served by Mount Sinai Hospital. Currently comprised of over 47,000 participants, BioMe participants are of African (AA, 24%), Hispanic/Latino (HL, 35%), European (EA, 32% of whom 40% Ashkenazi Jewish) and other/mixed ancestry.
BioMe is linked to Mount Sinai's system-wide Epic EHR, which captures a full spectrum of biomedical phenotypes, including clinical outcomes, covariate and exposure data from past, present and future health care encounters. The median number of outpatient encounters is 21 per participant, reflecting predominant enrollment of participants with common chronic conditions from primary care facilities. Clinical phenotype data has been meticulously harmonized and validated.
Genome-wide genotype data and whole exome sequencing data is available for >30,000 participants. In addition, whole genome sequencing data is available for >11,000 participants. The full electronic records of three BioMe LRRK2 pLoF carriers were reviewed by local clinicians and we were provided with detailed summaries.
Estonian Biobank of the Estonian Genome Center, University of Tartu
The Estonian Biobank cohort is composed of volunteers from the general Estonian resident adult population 42 . The current number of participants -close to 165,000--represents 15%, of the Estonian adult population, making it ideally suited to population-based studies. Participants were recruited throughout Estonia by medical personnel, and participants receive a standardized health examination, donate blood, and fill out a 16-module questionnaire on health-related topics such as lifestyle, diet and clinical diagnoses. A detailed phenotype summary from a health survey and linked data including ICD10 codes, clinical lab values and treatment and medication information is annually updated through linkage with national electronic health databases and registries.
23andMe variant annotation and curation
Putative LRRK2 LoF variants were defined as those classified as high-confidence by LOFTEE. Variants were manually assessed for call rate, genotyping and imputation quality and manually curated to ensure they were expected to cause true LoF.
For each of the two genotyped LRRK2 pLoF, we determined carrier status by manually inspecting and custom calling the probe intensity plots. For the imputed variants, carrier status was determined from the Minimac-Imputed dosage. As these calling methods might produce false positives, we confirmed the participants' genotypes through Sanger sequencing. This resulted in a cohort of 749 individuals, each of whom is a Sanger sequence-confirmed carrier for one of three pLoF variants (Supplementary Table 3 ).
During initial selection and sequencing, expansion of the database led to inclusion of a number of additional individuals genotyped for one of the pLoF variants, rs183902574. We performed customcalling on these individuals and found 354 deemed high-confidence carriers (Supplementary Table  3 ). As these individuals were not Sanger sequenced, all subsequent analyses were performed both including and excluding these individuals.
Association testing in the 23andMe dataset

Phenotype selection
The 23andMe dataset includes self-reported phenotype data for thousands of phenotypes across a diverse range of categories. These phenotypes have different sample sizes and prevalences, so the power to detect associations varies widely. We began with a curated set of 748 disease phenotypes. We then applied a liberal filter based on our power to detect an association with carrier status. More specifically, assuming a MAF of 2E-05, we restricted to phenotypes where we had power 0.1 to detect an association effect with OR > 1.3 (for binary traits) or beta > 0.2 (for quantitative traits) at alpha=0.0001 significance. This left us with 481 binary and 15 quantitative phenotypes.
Association testing
For each phenotype, we first restricted to individuals for whom we had phenotypic data. We calculated pairwise identity by descent (IBD) over all individuals using a modified version of IBD64, and then iteratively removed individuals until we were left with a set of participants, no two of whom shared > 700cM in IBD. We then tested the association between the phenotype and carrier status, controlling for age, sex, genotyping platform, and the first ten genetic principle components. We used logistic regression for binary phenotypes, and linear regression for quantitative phenotypes.
To control for population structure we restricted our analyses to participants with > 97% European ancestry, but the results did not qualitatively change when we dropped this restriction. We also tested associations using only individuals whose carrier status was confirmed by Sanger sequencing, but this also did not result in any meaningful difference.
Analysis of LRRK2 protein levels
Cell culture All cell lines tested negative for mycoplasma contamination on a monthly basis with the MycoAlert™ Detection kit (Lonza, LT07-118) and MycoAlert™ Assay Control Set (Lonza, LT07-518). Cells were grown at 37°C with 5% CO2.
Human embryonic stem cell culture
All pluripotent stem cells were approved by Harvard ESCRO protocol #E00052 and #E00067. Human embryonic stem cells (hESCs) were obtained from WiCell Research Institute (WA01, H1) under an MTA. Cell lines were authenticated by visual inspection of cell morphology with brightfield microscopy, staining with anti-Oct4 antibody to determine maintenance of pluripotency (Santa Cruz, sc-5279, data not shown), sent to WiCell Research Institute after 6 months of passaging or after isogenic cell line generation for karyotyping, and in some cases PCA of RNA sequencing data to confirm clustering with other pluripotent stem cell lines. Pluripotent stem cells were plated onto hESC qualified matrigel (VWR, BD354277) coated 6 well plates, mTeSR1 media was changed daily (StemCell Technologies, 85850), and cells were passaged every 5-7 days with 0.5mM EDTA.
Lymphoblastoid cell culture
Lymphoblastoid cell lines (LCLs) were obtained from Coriell Biorepository (GM18500, GM18501, GM18502, HG01345, HG01346) and approved by the Broad Institute Office of Research Subject Protection protocol #3639. Cell lines were authenticated by visual inspection of cell morphology with brightfield microscopy and in some cases PCA of RNA sequencing data to confirm clustering with GTEx LCLs. LCL media was changed every other day with RPMI 1640 (Life Technologies), 2mM L-glutamine (Life Technologies), and 15% FBS (Sigma).
Cardiomyocyte differentiation
Cardiomyocyte differentiation of the control and engineered H1 hESC lines was performed according to the protocol by Lian et al., 2012. Briefly, 500,000 cells were plated on hESC qualified matrigel (VWR, BD354277), grown in mTeSR1 media for four days (StemCell Technologies, 85850), and switched to RPMI media (Life Technologies) with B27 supplement (Life Technologies), switching to B27 with insulin at day 7, for the remainder of the protocol. On day 0 of differentiation, 12µM CHIR99021 (Tocris) was applied for 24 hours. At day 3, cultures were treated with 5µM IWP2 (Tocris) for 24 hours. Bright field images and movies were acquired at day 17 and cells were harvested for protein/RNA extraction at day 19.
Isogenic cell line engineering
The following guide and HR template were delivered into single cell H1 hESCs via nucleofection (Lonza 4D-Nucleofector X unit) using the P3 Primary Cell Kit (V4XP-3024), pulse code CA137, and pX459 (Addgene): AATAAGGCATTTCATATAGT and ACAGGCCTGTGATAGAGCTTCCCCATTGT GAGAACTCTGAAATTATCATCTGACTATATGAAATGCCTTATTTTCCAATGGGATTTTGGTCAAGATTAA. Cells were allowed to recover from nucleofection in mTeSR supplemented with 10µM Rock Inhibitor (Y-27632, Tocris) overnight. The following three days the cells were treated with 0.25µg/ml puromycin (VWR) in mTeSR. Cells were then cultured in mTeSR until colonies were ready to be split. Engineered cells were split into single cells and plated in matrigel coated 96-well plates at a density of 0.5 cells per well. Plates were screened for colonies 8-10 days after plating and grown until colonies were ready to be split. Colonies were then split with 0.5mM EDTA into two identical 96-well plates, one for DNA extraction/PCR/sequencing and one for freezing cells. Once colonies were ready to be split, 96-well plates were frozen in mFreSR (Stem Cell Technologies) and stored at -80°C until HR positive wells were identified. HR edited cells were then thawed and expanded for 4 generations, validated by Sanger sequencing, karyotyping, and OCT4 staining prior to proceeding with cardiomyocyte differentiation.
Off-target analysis of CRISPR/Cas9 engineering
To detect any potential off-target effects caused by CRISPR/Cas9 genome editing, whole-genome sequencing (WGS) was conducted for both the engineered and control cell lines. DNA extraction, Quality Control (QC) and 30x PCR-Free WGS were performed by the Genomics Platform at the Broad Institute. AllPrep DNA/RNA extraction kit was used, following its protocol. Alignment, marking of duplicates, recalibration of quality scores and variant calling are all performed using GATK best practices 43 .
We identified 157,230 variants in the engineered cell line that were not found in the control cell line as candidate variants. For the guide RNA (gRNA) used, we defined potential off-target regions as those with <4bps mismatch against the full 20bp gRNA sequence (334 regions), and/or <2bp mismatch against the seed (=PAM proximal) 12bp of the gRNA sequence (5,780 regions), each followed by the NGG PAM. We looked for any candidate variant that fall into the potential off-target region, resulting in detection of only one variant (chr8-65084564-A-AT) that falls onto a region with 1 mismatch against the seed 12bp of gRNA sequence (chr8:65084560-65084575). No variants with <4bp mismatch against the full 20bp gRNA sequence or perfect match at the seed region were detected. Since a mismatch at the seed region decreases the likelihood of off-target variants 44, 45 , and also because the single variant we detected is a known variant (rs1161563412) observed in the population without apparent phenotypic association, we concluded no major off-target effect exists at the level of violating the main steps of our research. All the analysis for the detection of potential off-target were conducted using pybedtools 46 and CRISPRdirect 47 software.
Western blot analysis
Cell pellets were snap-frozen in liquid nitrogen and stored at -80°C. Cells were dounce homogenized in ice-cold radioimmunoprecipitation assay buffer (RIPA) (89901; Thermo Scientific) containing protease inhibitors (HaltTM Protease Inhibitor, Thermo Scientific). Homogenates were rotated at 4°C for 30min, followed by centrifugation at 15,000g for 20min at 4°C. Equal amounts of protein (50µg) were electrophoresed on 4-20% SDS-PAGE (Biorad) and transferred to nitrocellulose membranes. The following antibodies were used for immunoblotting: LRRK2 (75-253, UC Davis/NIH NeuroMab Facility), α-actinin (A7811, Sigma), GAPDH (sc-25778, Santa Cruz), anti-rabbit IgG HRP (7074, Cell Signaling), and anti-mouse IgG HRP (7076, Cell Signaling). Immunoblots were developed using enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate, Thermo Scientific) on an Amersham Imager 600.
